A Two-part Study To Assess the Safety and Preliminary Efficacy of Givinostat in Patients With JAK2V617F Positive Polycythemia Vera
Phase of Trial: Phase I/II
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Givinostat (Primary)
- Indications Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
- Sponsors Italfarmaco
- 07 Jun 2017 Biomarkers information updated
- 01 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 01 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2017.